SGLT2 versus DPP-4 Inhibitors: Modest Glycemic Edge, Consistent Weight Benefit

This dose-stratified meta-analysis quantifies the head-to-head glycemic, weight, and genital-infection tradeoffs between two common second-line oral agents in type 2 diabetes.

SGLT2 inhibitorsDPP-4 inhibitorsempagliflozincanagliflozindapagliflozinertugliflozinsitagliptinlinagliptintype 2 diabetesHbA1cweight lossgenital infectionmeta-analysisglycemic control Endocrinology / Diabetes / Obesity

Background Information

SGLT2 inhibitors excel in control but risk infections.

Selecting appropriate glucose-lowering drugs is essential for individualized patient care in type 2 diabetes, balancing efficacy with safety concerns. High-dose sodium-glucose linked transporter 2 inhibitors (SGLT2i) demonstrated superior glycemic control compared to dipeptidyl peptidase 4 inhibitors (DPP4i), and all SGLT2i doses were more effective in weight reduction, but they increased genital infection risk. While high-dose SGLT2i offer better glycemic control, they pose a higher infection risk; clinicians must tailor therapy based on individual patient profiles and priorities. SGLT2i offer more effective glycemic control and weight loss than DPP4i but increase the risk of genital infections.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Fang X, Li R, Liu S, Zou X, Zhong Y, Yang Y

Citation: Fang X, Li R, Liu S, et al. SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a meta-analysis of outcomes. Frontiers in endocrinology. 2026;17:1930813. doi:10.3389/fendo.2026.1930813

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →